BTK inhibitors such as tolebrutinib or evobrutinib work about as well as Aubagio at preventing relapses in MS, a review of ...
Molecular imaging is redefining in vivo characterization of multiple sclerosis, a demyelinating disease with complex and heterogeneous clinical profiles. Recent advances in PET tracers enable more ...
Immunic presents additional phase 2 CALLIPER trial data for vidofludimus calcium in patients with progressive MS at the ACTRIMS Forum 2026: New York Friday, February 6, 2026, 16:0 ...
Weiss, Chief Executive Officer and Chairman of TG Therapeutics stated, “We are pleased to share data at this year’s ACTRIMS annual meeting, including updates from the ENABLE real world study ...
Teva Canada and Novartis Canada are collaborating to ensure continued access to Mayzent for people with active SPMS in Canada ...
MedPage Today on MSN
Case study: Do these symptoms really indicate a stroke?
Getting to the bottom of the cause in this 29-year-old woman illustrates the diagnostic co ...
Following AQUA and SCALE PET, the latest FDA clearance reinforces Neurophet's leadership in AI-based Alzheimer's disease ...
The National on MSN
MS will not hold us back, say athletes gearing up for Open Masters Games in Abu Dhabi
Residents living with the condition will compete alongside international athletes across Abu Dhabi and Al Dhafra ...
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and gastrointestinal diseases, today announced the presentation of ...
A new study reveals how Epstein-Barr virus may provoke immune cells to attack the brain, offering fresh hope for treating ...
What are the often invisible cognitive consequences of multiple sclerosis? Maureen van Dam mapped these out during her ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results